NEW ORLEANS – On Saturday a new study showed that Nexletol, the cholesterol-lowering medicine made by Esperion Therapeutics, prevented heart attacks among people who cannot or will not take potent cholesterol-lowering statins.
The question now is whether those benefits are going to be enough to make sales of Nexletol take off. They have been basically dead in the water since the oral medicine was approved three years ago.
Investors will be looking to see whether Esperion, a small company that has seen its stock slide significantly, can mount a big enough marketing campaign to help reignite sales. Here are some questions – and answers – from the annual meeting of the American College of Cardiology, where the Nexletol data were presented.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect